Replies to post #2218 on Insmed Inc (INSM)

[coinstarz]

This is a very good research. If rhIGFBP3 can touch breast cancer area with a big phrama firm even with pre-clinic study, INSM will fly. Breast cancer is a huge market. Let's see what Jelly, drbio, chem, and other good poster with strong bio/phrama background will say.